NEW YORK CITY, NY / ACCESS Newswire / October 20, 2025 / NEW YORK, NY / ACCESS Newswire / October 20, 2025 / If you suffered a loss on your Fly-E Group, Inc. (NASDAQ:FLYE) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: […]
NEW YORK CITY, NY / ACCESS Newswire / October 20, 2025 / NEW YORK, NY / ACCESS Newswire / October 20, 2025 / If you suffered a loss on your Lantheus Holdings, Inc. (NASDAQ:LNTH) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information:
NEW YORK CITY, NY / ACCESS Newswire / October 20, 2025 / NEW YORK, NY / ACCESS Newswire / October 20, 2025 / If you suffered a loss on your V.F. Corporation (NYSE:VFC) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/v-f-corporation-lawsuit-submission-form?prid=172956&wire=1&utm_campaign=3
(NYSE MKT:CATX), Updated interim results with an additional ~19 weeks of follow-up since the prior update [212Pb]VMT-α-NET continues to be well-tolerated Objective Response Rate of 44% (7 of 16 patients) in Cohort 2 with SSTR2 expression in all tumors at median follow-up of 41 weeks; 14 of the 16 patients remain free from progression and
Highlights from the national survey include: 74% of Canadian SMEs took steps to improve productivity this year; nearly one-third (30%) leveraged new technologies. While 86% report being in good health, 54% experienced emotional or mental exhaustion during the year. More than half (55%) of entrepreneurs aim for moderate to strong growth in the coming year.
(NasdaqGM:NIU), BEIJING, Oct. 20, 2025 (GLOBE NEWSWIRE) — Niu Technologies (“NIU” or “the Company”) (NASDAQ: NIU), the world's leading provider of smart urban mobility solutions, today announced that it will report its financial results for the third quarter 2025 before the U.S. market opens on Monday, November 17, 2025. The corporate presentation and financial spreadsheets
Partial remissions and complete metabolic responses in PD-1/PD-L1-resistant cancers First-in-class multi-checkpoint inhibitor with robust efficacy and safety Combination arm with pembrolizumab (Keytruda(R)) in Australia near to completion by end 2025 Schlieren, Switzerland, October 20, 2025 – ImmunOs Therapeutics AG, a clinical-stage biopharmaceutical company leveraging its unique immune system modulating HLA-based technology platform to develop first-in-class
Niu Technologies to Report Third Quarter 2025 Financial Results on November 17, 2025 GlobeNewswire October 20, 2025 BEIJING, Oct. 20, 2025 (GLOBE NEWSWIRE) — Niu Technologies (“NIU” or “the Company”) (NASDAQ: NIU), the world's leading provider of smart urban mobility solutions, today announced that it will report its financial results for the third quarter 2025
ImmunOs Therapeutics Reports Promising Clinical Activity of IOS-1002 in Advanced Solid Tumors GlobeNewswire October 20, 2025 Partial remissions and complete metabolic responses in PD-1/PD-L1-resistant cancers First-in-class multi-checkpoint inhibitor with robust efficacy and safety Combination arm with pembrolizumab (Keytruda(R)) in Australia near to completion by end 2025 Schlieren, Switzerland, October 20, 2025 – ImmunOs Therapeutics AG,
Perspective Therapeutics Presents Updated Interim Data from its Ongoing Phase 1/2a Clinical Trial of [212Pb]VMT-α-NET at the ESMO Congress 2025 GlobeNewswire October 20, 2025 Updated interim results with an additional ~19 weeks of follow-up since the prior update [212Pb]VMT-α-NET continues to be well-tolerated Objective Response Rate of 44% (7 of 16 patients) in Cohort 2